The University of Oxford has launched the first human clinical trial of a vaccine targeting the Bundibugyo strain of the Ebola virus, marking a significant step towards strengthening global preparedness against one of the deadliest viral diseases. The early-stage study will assess the safety and immune response of the experimental vaccine in healthy adult volunteers.

The Phase I trial, named BD-Ebov, will evaluate the ChAdOx1 BDBV vaccine in 50 healthy adults aged 18–55 years in Oxford. Researchers will examine the vaccine’s safety profile and its ability to generate an immune response against the Bundibugyo ebolavirus (BDBV), a less common but highly lethal species of the Ebola virus.

The vaccine is based on Oxford’s ChAdOx1 viral vector platform, the same technology that was successfully used in developing the Oxford-AstraZeneca COVID-19 vaccine. Scientists believe the platform could accelerate the development of effective vaccines against emerging infectious diseases, including Ebola.

Although outbreaks caused by the Bundibugyo strain are relatively rare, the virus has been responsible for several deadly outbreaks in Africa, with reported case fatality rates of around 25–50%, according to the World Health Organization (WHO). Currently, approved Ebola vaccines primarily target the Zaire ebolavirus, leaving limited protection against other Ebola species.

Researchers said the trial is part of broader global efforts to develop vaccines against multiple Ebola strains to strengthen outbreak preparedness. If the vaccine demonstrates favourable safety and immune responses, it could progress to larger clinical trials in regions at risk of Ebola transmission.

Healthcare experts have welcomed the initiative, noting that expanding the pipeline of strain-specific Ebola vaccines is essential for improving global health security. They said the trial represents an important milestone in pandemic preparedness and could help strengthen future responses to emerging viral outbreaks.